C. diff Risk


Oral Bioavailability

Moderate (40 to 70%)

Approximate Cost


Spectrum Of Activity

General Information

Common Usage

  • For the treatment of herpes zoster (shingles).

  • For the treatment or suppression of genital herpes in immunocompetent individuals and for the suppression of recurrent genital herpes in HIV infected individuals.

  • To reduce the risk of transmission of genital herpes with the use of suppressive therapy.

  • For the treatment of cold sores (herpes labialis).

Adverse Effects

  • Headache

  • Nausea

  • Acute kidney injury

  • Increased AST and ALT

  • CNS effects (agitation, hallucinations, confusion and encephalopathy)

  • Thrombotic Thrombocytopenia Purpura/Hemolytic Uremic Syndrome (TTP/HUS)

Major Interactions

No clinically significant interactions have been identified. Screen drug specific interactions for interactions via CYP 1A2 and pharmacodynimc adverse effects.

Increased risk of nephrotoxicity when used concomitantly with other nephrotoxic agents.

Tablet/Capsule Strengths

No restrictions

Additional Information

EH Prescribing Restrictions

Tablets can be crushed for NG administration

No liquid formulation available

ValACYclovir is a prodrug of the antiviral acyclovir.

ValACYclovir is rapidly and nearly completely converted to acyclovir